Company Overview
Aura Biosciences, Inc. operates as a clinical-stage biotechnology entity dedicated to developing precision therapies specifically designed to treat solid tumors. The company leverages a proprietary platform that facilitates the targeting of various solid tumors by utilizing virus-like particles, which are either conjugated with drugs or loaded with nucleic acids to create virus-like particles for therapeutic delivery. This organization functions within the healthcare sector, specifically the biotechnology industry, positioning it as a specialized developer focused on advanced oncology treatments rather than broad pharmaceutical production. In terms of scale, the company holds a market capitalization of $411.50M and employs 106 individuals to execute its research and development strategies. The valuation indicates a mid-stage biotechnology profile, where the market cap reflects investor sentiment regarding the potential of its pipeline despite the absence of significant annual revenue figures currently reported, highlighting the capital-intensive nature of its current operational phase.
Financial Health
Aura Biosciences, Inc. reports a net income of $-106,466,000 and an EBITDA of $-112,213,000 for the trailing twelve months, while annual revenue figures are not publicly disclosed. The substantial gap between the reported net income and EBITDA, both of which are deeply negative, reveals a cost structure characterized by high operating expenses typical of clinical-stage development, where costs related to research, clinical trials, and administrative overhead significantly outpace any current sales income. The company generated free cash flow of $-51,435,624 during the same period, indicating a continuous burn rate that necessitates external capital raising to maintain operations and fund future clinical milestones. Analyzing the three reported margins shows that the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, which collectively indicate that the company is currently pre-revenue or operating at a loss where revenue has not yet covered the costs of goods sold or general operations. Despite these negative income statements, the company maintains a cash balance of $161.87M against a total debt load of $17.75M, resulting in a debt-to-equity ratio of 11.33, which suggests a balance sheet that is heavily leveraged relative to equity but currently unencumbered by immediate solvency crises given the cash reserve. The current ratio stands at 9.04, a figure that indicates robust short-term liquidity and an ability to meet its current liabilities with assets more than nine times the required amount. Furthermore, the return on equity is -64.3% and the return on assets is -35.8%, metrics that reveal management is currently deploying capital to generate negative returns in the short term, a common characteristic for companies in the early stages of product development before commercialization begins.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -3.19, implying that expected earnings remain negative in the near future and that traditional multiple analysis is currently inapplicable to this stock. The price-to-book ratio is 2.61, suggesting that the market values the company at a premium of 2.61 times its net asset value, likely reflecting the intangible value of its proprietary platform and potential future clinical assets rather than its book value alone. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not applicable or negative, with the EV/EBITDA standing at -2.38, indicating that the enterprise value is currently detached from current earnings power and driven entirely by asset and pipeline potential. The stock has experienced significant price movement within the last year, trading between a 52-week low of $4.34 and a 52-week high of $7.73, placing the current trading price within a range that reflects high volatility typical of small-cap biotechnology firms. The beta value of 0.45 indicates that the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the overall index, which offers a degree of stability uncommon for biotechnology equities despite the company's high-risk developmental stage.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not applicable, as the company has not generated positive revenue or earnings to establish a growth trajectory for comparison. Because the company does not pay dividends, there is no dividend yield or payout ratio to analyze, meaning the payout ratio is effectively 0.0% as all available cash flow is retained within the company to fund its clinical trials and operational needs. The absence of a dividend yield confirms that the company reinvests all generated funds and cash reserves directly back into research and development efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for future clinical successes and regulatory approvals, rather than current cash distributions or historical earnings expansion.